Hygea vct provides investors with access to a diversified portfolio of emerging and established MedTech companies qualifying for investment by a VCT. The board has a strong track record of investing in this area and has a network of personnel with successful P&L responsibility experience in the MedTech sector, both in the UK and internationally.

A key feature of the Hygea investment approach is to ensure that portfolio companies are developed as solutions companies i.e. compete on the basis of value provided to customers (not price) by providing better patient outcomes at lower total cost. The effect of this approach is that portfolio companies tend to be focused around medical devices, drug delivery systems, diagnostics and technology based support services - standalone molecule development companies do not generally qualify as solutions companies.